^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LIPI (Lipase I)

    i
    Other names: LIPI, Lipase I, Cancer/Testis Antigen 17, CT17, LPDL, Membrane-Associated Phosphatidic Acid-Selective Phospholipase A1-Beta, Lipase Member I, MPA-PLA1 Beta, LPD Lipase, PLA1C, PRED5, Membrane-Associated Phospholipase A1 Beta, MPA-PLA1beta
    2years
    QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors. (PubMed, Saudi Pharm J)
    Based on the results obtained by molecular modeling, we proposed six new compounds (Pred1, Pred2, Pred3, Pred4, Pred5, and Pred6) with highly significant predicted activity by MLR models. A study based on the in silico evaluation of the predicted ADMET properties of the new candidate molecules is strongly recommended to classify these molecules as promising candidates for new anticancer agents specifically designed to target Bruton's tyrosine kinase (BTK) inhibition.
    Journal
    |
    LIPI (Lipase I)
    almost5years
    A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, University of Colorado, Denver | Phase classification: P=N/A --> P1
    Phase classification
    |
    LIPI (Lipase I)
    almost5years
    Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Duke University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LIPI (Lipase I)
    almost5years
    SHADES: Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions (clinicaltrials.gov)
    P=N/A, N=700, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LIPI (Lipase I)
    almost5years
    RETINO2018: Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome (clinicaltrials.gov)
    P2/3, N=225, Recruiting, Institut Curie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LIPI (Lipase I)
    |
    carboplatin • etoposide IV • vincristine • topotecan • melphalan
    almost5years
    Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL (clinicaltrials.gov)
    P3, N=250, Recruiting, Loxo Oncology, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LIPI (Lipase I)
    |
    Rituxan (rituximab) • Zydelig (idelalisib) • Jaypirca (pirtobrutinib) • bendamustine
    almost5years
    ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, University of Calgary
    New trial
    |
    LIPI (Lipase I)
    almost5years
    Micro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINE (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Jules Bordet Institute
    New trial
    |
    LIPI (Lipase I)
    almost5years
    Promoting Equity for Cancer Screening and Follow-up (clinicaltrials.gov)
    P=N/A, N=1800, Not yet recruiting, Mayo Clinic
    New trial
    |
    LIPI (Lipase I)
    almost5years
    BIHNC: Body Image After Head and Neck Cancer Treatment (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Bethany Rhoten
    New trial
    |
    LIPI (Lipase I)
    almost5years
    68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, British Columbia Cancer Agency
    New trial
    |
    LIPI (Lipase I)
    almost5years
    Aberrant DNA Methylation to Predict Metachronous Gastric Neoplasms (clinicaltrials.gov)
    P, N=300, Completed, Seoul National University Hospital
    New trial
    |
    LIPI (Lipase I)